Go to Header
Go to Navigation
Go to Content
Go to Footer
Login
Help
中文(繁體)
Research Resources
CUHK UPDates
Theses
Experts List
User Guides
About Us
List of Researchers
> Professor Lam CHAN
Home
Research Outputs
Researcher Profiles
Department Profiles
Research Areas
Professor CHAN Lam
Personal Information
Position and Department
Professor
,
Department of Clinical Oncology
ORCiD
0000-0001-8998-5480
ResearcherID
F-9149-2011
CUHK Research Outputs
1 of 8
A Liver Stiffness-Based Etiology-Independent Machine Learning Algorithm to Predict Hepatocellular Carcinoma
(
2024
)
Clinical Management of Gastrointestinal and Liver Toxicities of Immune Checkpoint Inhibitors
(
2024
)
Genomic origin, fragmentomics, and transcriptional properties of long cell-free DNA molecules in human plasma
(
2024
)
Hong Kong consensus recommendations on the management of pancreatic ductal adenocarcinoma
(
2024
)
Methylation-associated nucleosomal patterns of cell-free DNA in cancer patients and pregnant women
(
2024
)
Achievement of Complete Response and Drug-free Status by Atezolizumab Plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization-Unsuitable, Intermediate-stage Hepatocellular Carcinoma: A Multicenter Proof-of-Concept Study
(
2023
)
A liver stiffness-based aetiology-independent machine learning algorithm to predict hepatocellular carcinoma
(
2023
)
A Selective Class I HDAC Inhibitor Recovers Intratumoral Interferon Signaling to Overcome Immune-checkpoint Blockade Resistance in Hepatocellular Carcinoma
(
2023
)
Baveno VII criteria identify varices needing treatment in patients with hepatocellular carcinoma of different Barcelona Clinic Liver Cancer stages
(
2023
)
Baveno VII Criteria Is an Accurate Risk Stratification Tool to Predict High-Risk Varices Requiring Intervention and Hepatic Events in Patients with Advanced Hepatocellular Carcinoma
(
2023
)
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
(
2023
)
Dramatic increase in use of immunotherapy for hepatocellular carcinoma (HCC) – a territory-wide study from 2015-2022
(
2023
)
Duration of type 2 diabetes and liver-related events in nonalcoholic fatty liver disease: A landmark analysis
(
2023
)
Efficacy and safety of lenvatinib in patients with recurrent hepatocellular carcinoma after liver transplantation
(
2023
)
Epigenetic activation of tumoral IFNγ response and pyroptosis overcomes immunotherapy resistance in hepatocellular carcinoma
(
2023
)
Epigenetic Remodeling of Endothelial Cells underlying Immune Checkpoint Resistance in Hepatocellular Carcinoma
(
2023
)
First-line Systemic Therapies for Advanced Hepatocellular Carcinoma: A Systematic Review and Patient-Level Network Meta-Analysis
(
2023
)
Fragmentation landscape of cell-free DNA revealed by deconvolutional analysis of end motifs
(
2023
)
Frequency- and type-dependent impacts of concomitant usage of H1-antihistamines on survival in patients with primary liver cancers treated with immune checkpoint inhibitors
(
2023
)
Isoformic PD-1-mediated immunosuppression underlies resistance to PD-1 blockade in hepatocellular carcinoma patients
(
2023
)
Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer Term Follow-Up from the Phase 3 KEYNOTE-240 Trial
(
2023
)
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliarytract cancer (KEYNOTE-966) : a randomised, double-blind, placebo-controlled, phase 3 trial
(
2023
)
Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer)
(
2023
)
Plasma Epstein–Barr Virus DNA and Risk of Future Nasopharyngeal Cancer
(
2023
)
Predicting cancer immunotherapy responses through machine learning of single-cell transcriptomes
(
2023
)
Recent Advances in Systemic Therapy for Advanced Intrahepatic Cholangiocarcinoma
(
2023
)
Recommendations for the use of next-generation sequencing in patients with metastatic cancer in the Asia-Pacific region: a report from the APODDC working group
(
2023
)
Risk of hepatitis B virus reactivation in hepatocellular carcinoma patients with current or past hepatitis B infection receiving immunotherapy: a territory-wide cohort study
(
2023
)
Risks and impacts of thromboembolism in patients with pancreatic cancer
(
2023
)
Single-cell Landscape of Cancer-associated Fibroblasts in Immunotherapy Resistance of Hepatocellular Carcinoma
(
2023
)
Systemic treatment in child PUGH B patients with hepatocellular carcinoma
(
2023
)
Targeting PPAR-gamma counteracts tumour adaptation to immune-checkpoint blockade in hepatocellular carcinoma
(
2023
)
The combination of ALBI and AFP response: A small step forward in HCC
(
2023
)
The Evolving Role of Lenvatinib at the New Era of First-Line HCC Treatment
(
2023
)
The prime time for management of hepatocellular carcinoma in Hong Kong
(
2023
)
The role of lenvatinib in the era of immunotherapy of hepatocellular carcinoma.
(
2023
)
Trends in risk factor control and treatment among patients with non-alcoholic fatty liver disease and type 2 diabetes between 2000 and 2020: A territory-wide study
(
2023
)
Tumor cell-macrophage crosstalk promotes immunotherapy resistance via lipid metabolism
(
2023
)
Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region
(
2023
)
Age and the relative importance of liver-related deaths in nonalcoholic fatty liver disease
(
2022
)
Age and the relative importance of liver-related deaths in non-alcoholic fatty liver disease
(
2022
)
A Selective Class I Hdac Inhibitor Recovers Intratumoral Interferon Signaling to Overcome Immune-checkpoint Blockade Resistance in Hepatocellular Carcinoma
(
2022
)
Baveno VII criteria identify varices needing treatment in patients with hepatocellular carcinoma of different BCLC stages undergoing curative hepatectomy
(
2022
)
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312) : a multicentre, open-label, randomised, phase 3 trial
(
2022
)
CircRTN4 promotes pancreatic cancer progression through a novel CircRNA-miRNA-lncRNA pathway and stabilizing epithelial-mesenchymal transition protein
(
2022
)
Comparison of chemoembolization, radioembolization, and transarterial ethanol ablation for huge hepatocellular carcinoma (≥10cm) in tumour response and long-term survival outcome
(
2022
)
Could We Predict the Response of Immune Checkpoint Inhibitor Treatment in Hepatocellular Carcinoma?
(
2022
)
Drug Treatment for Advanced Hepatocellular Carcinoma: First-Line and Beyond
(
2022
)
Epigenetic analysis of cell-free DNA by fragmentomic profiling
(
2022
)
Epigenetic Remodeling of Endothelial Cells underlying Immune Checkpoint Resistance in Hepatocellular Carcinoma
(
2022
)
Share Link
Last updated on 2024-03-09 at 16:09
Share Link
Your name*
Your email*
Recipient's name*
Recipient's email*
Message
Auxilliary Information
No information will be stored or shared with any third party.
Cancel
Our policy towards the use of cookies
All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Ok to Continue
Cookie Policy